Rallybio
Unimagined therapies. Undreamed outcomes.
New Haven, United States
39 employees
Post Ipo Equity
Total: $238.60M
Biopharma, Biotechnology +2
General Information
Get notified when Rallybio moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Rallybio
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Biopharma
About Rallybio
Taxonomy: clinical-stage, therapies, rare diseases, maternal fetal health, complement dysregulation, hematology, metabolic disorders, anti-HPA-1a antibody, fetal and neonatal alloimmune thrombocytopenia, complement component 5 inhibitor, University of Connecticut, technology incubation program, New Haven, Connecticut
Funding Rounds & Investors (5)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | •••••• | 1 | •••• •••• | 10 Apr 2024 |
| Post-IPO Equity | •••••• | - | 10 Nov 2022 | |
| Series B | •••••• | 9 |
|
14 Apr 2020 |
| Venture Round | •••••• | - | 01 Oct 2019 | |
| Series A | •••••• | - | 25 Apr 2018 |
Rallybio Alternatives & Competitors
Our vision is to provide effective and safe RNA therapeutics to patients who suffer from intractable...
Developing the next generation of complement medicines
Catalyst is a research and clinical development biopharmaceutical company focused on addressing unme...
FAQ About Rallybio
Don't just browse. Track.
Signal Tracker monitors Rallybio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.
